| Identification | Back Directory | [Name]
Ruthenium, dichloro[(1,2,3,4,5,6-η)-1-methyl-4-(1-methylethyl)benzene](1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane-κP7)- | [CAS]
372948-28-2 | [Synonyms]
RAPTA-C
Ruthenium, dichloro[(1,2,3,4,5,6-η)-1-methyl-4-(1-methylethyl)benzene](1,3,5-triaza-7-phosphatricyclo[3.3.1.13,7]decane-κP7)- | [Molecular Formula]
C16H23Cl2N3PRu | [MOL File]
372948-28-2.mol | [Molecular Weight]
460.32 |
| Hazard Information | Back Directory | [Description]
RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. | [Uses]
RAPTA-C (Ru(η6-p-cymene)Cl2(pta)) acts as an anti-cancer and anti-angiogenic agent. RAPTA-C exhibits anti-metastatic, anti-angiogenic, and anti-tumoral activities through protein and histone-deoxyribonucleic acid alterations. RAPTA-C exhibits cell growth inhibition by triggering G(2)/M phase arrest in cancer cells. RAPTA-C also enhances the levels of p53 and triggers the mitochondrial Apoptotic pathway, resulting in cytochrome C release and caspase-9 activation. RAPTA-C reduces the growth of tumors with the inhibition of angiogenesis in a ovarian carcinoma model[1][2][3]. | [References]
[1] Rausch M, et al. Recent considerations in the application of RAPTA‐C for cancer treatment and perspectives for its combination with immunotherapies[J]. Advanced Therapeutics, 2019, 2(9): 1900042.
[2] Weiss A, et al. In vivo anti-tumor activity of the organometallic ruthenium (II)-arene complex [Ru (η 6-p-cymene) Cl 2 (pta)](RAPTA-C) in human ovarian and colorectal carcinomas[J]. Chemical Science, 2014, 5(12): 4742-4748.
[3] Chatterjee S, et al. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J Biol Inorg Chem. 2008 Sep;13(7):1149-55. DOI:10.1007/s00775-008-0400-9 |
|
|